Virtus ETF Advisers’s ALX Oncology ALXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-10,920
| Closed | -$19.9K | – | 467 |
|
|
2024
Q3 | $19.9K | Buy |
10,920
+194
| +2% | +$353 | 0.01% | 451 |
|
|
2024
Q2 | $64.7K | Buy |
10,726
+4,160
| +63% | +$25.1K | 0.03% | 439 |
|
|
2024
Q1 | $73.2K | Sell |
6,566
-453
| -6% | -$5.05K | 0.04% | 404 |
|
|
2023
Q4 | $105K | Sell |
7,019
-3,708
| -35% | -$55.2K | 0.07% | 340 |
|
|
2023
Q3 | $51.5K | Sell |
10,727
-1,067
| -9% | -$5.12K | 0.03% | 414 |
|
|
2023
Q2 | $88.6K | Buy |
11,794
+2,775
| +31% | +$20.8K | 0.05% | 418 |
|
|
2023
Q1 | $40.8K | Sell |
9,019
-3,465
| -28% | -$15.7K | 0.02% | 435 |
|
|
2022
Q4 | $141K | Sell |
12,484
-3,272
| -21% | -$36.9K | 0.07% | 364 |
|
|
2022
Q3 | $151K | Buy |
15,756
+115
| +0.7% | +$1.1K | 0.06% | 353 |
|
|
2022
Q2 | $127K | Buy |
15,641
+9,176
| +142% | +$74.5K | 0.05% | 362 |
|
|
2022
Q1 | $109K | Sell |
6,465
-379
| -6% | -$6.39K | 0.05% | 289 |
|
|
2021
Q4 | $147K | Buy |
6,844
+3,318
| +94% | +$71.3K | 0.06% | 354 |
|
|
2021
Q3 | $260K | Sell |
3,526
-192
| -5% | -$14.2K | 0.11% | 214 |
|
|
2021
Q2 | $203K | Sell |
3,718
-40
| -1% | -$2.18K | 0.08% | 333 |
|
|
2021
Q1 | $277K | Buy |
3,758
+70
| +2% | +$5.16K | 0.12% | 258 |
|
|
2020
Q4 | $318K | Buy |
+3,688
| New | +$318K | 0.13% | 194 |
|